GladmanD.D., UrowitzM.B.. Clinical features. In: SchumacherH.R. ed. Primer on the rheumatic diseases.10th ed.Atlanta: Arthritis Foundation, 1993: 106–12.
3.
MillsJ.A.. Systemic lupus erythematosus. N Engl J Med1994; 330: 1871–9.
4.
SpruillW.J., WadeW.E.. Other connective tissue disorders and the use of glucocorticoids. In: Koda-KimbleM.A., YoungL.Y. eds. Applied therapeutics.5th ed.Vancouver, WA: Applied Therapeutics, Inc., 1992: 1–15.
5.
KlippelJ.H.. Treatment. In: SchumacherH.R. ed. Primer on the rheumatic diseases.10th ed.Atlanta: Arthritis Foundation, 1993: 112–6.
6.
AchiranA, CohenI.R., LiderO, MelamedE. Intravenous immunoglobulin treatment in multiple sclerosis. Isr J Med Sci1995; 31: 7–9.
7.
SilvermanE.D., CawkwellG.D., LovellD.J., LaxerR.M., LehmanT.J., PassoM.H.Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol1994; 21: 2353–8.
8.
RondaN, HauryM, NobregaA, CoutinhoA, KazatchkineM.D.. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIG). Clin Immunol Immunopathol1994; 70: 124–8.
9.
GaedickeG, TellerW.M., KohneE, DopferR, NiethammerD. IgG therapy in systemic lupus erythematosus — two case reports. Blut1984; 48: 387–90.
10.
WinderA, MoladY, OstfeldI, KenetG, PinkhasJ, SidiY. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol1993; 20: 495–8.
11.
FrancioniC, GaleazziM, FioavantiA, GelliR, MegaleF, MarcolongoR. Long term I.V. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol1994; 12: 163–8.
12.
TanE.M., CohenA.S., FriesJ.F., MasiA.T., McShaneD.J., RothfieldN.F.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–7.
13.
KlippelJ.H.. Is aggressive therapy effective for lupus?Rheum Dis Clin North Am1993; 19: 249–61.
14.
OchsH.D., BuckleyR.H., PirofskyB, FischerS.H., RousellR.H., AndersonC.J.Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet1980; 2: 1158–9.
15.
Ben-ChetritE, PuttermanC. Transient neutropenia induced by intravenous immune globulin (letter). N Engl J Med1992; 326: 270–1.
CantuT.G., Hoen-SaricE.W., BurgessK.M., RacusenL, ScheelP.J.. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis1995; 25: 228–34.
24.
WinwardD.B., BrophyM.T.. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy1995; 15: 765–72.
BallowM. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer1991; 68: 1430–6.
27.
BradleyJ.D., BrandtK.D., KatzB.P.. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum1989; 32: 45–53.
